India's drug regulator CDSCO refuses to waive local trials for lenacapavir, blocking access to revolutionary HIV prevention for 25 lakh Indians. Learn why this happens despite drug being manufactured in India.
Patna High Court mandates regulatory guidelines for Bihar hospitals after infant loses mother at unregistered facility. Justice directs compensation and education for child.
West Bengal commission directs Fortis Hospital to refund laundry and biomedical waste disposal fees. Hospital told to remove these charges from billing system and repay all affected patients.
Kerala High Court issues 15 crucial directives for hospitals including rate displays, emergency care protocols, and grievance redressal systems to protect patient rights under 2018 Act.
Indian AI companies are unlocking value from unstructured clinical data, creating a $20 billion market opportunity. Discover how this revolution transforms healthcare diagnostics.
National Cancer Institute expands collaboration with Medidata to provide seamless medical data continuity for lead protocol organizations, advancing cancer research globally.
Anandita Kumar, born with cerebral palsy and heart defect, graduates from Pune University, becomes certified clinical musician and inspires others with disabilities.
Health authorities seal 31 private clinics in Palamu for Clinical Establishment Act violations. DC orders continued crackdown on unregistered facilities. Read about the health safety drive.
India's $8 billion nutraceutical market faces skepticism as startups invest in clinical trials and transparency to build consumer confidence in health supplements.
Discover how Democratic Socialist Zohran Mamdani's surprising election win reflects New York City's growing discontent with establishment politics and economic inequality.
Revolutionary drug-eluting stent demonstrates superior safety and efficacy across multiple international studies, setting new standards in cardiovascular care.
In a significant setback for gene editing medicine, Intellia Therapeutics halts its Phase 3 ATTR trial following a serious liver adverse event in a patient receiving CRISPR-based treatment NZ-1.